Suggested remit: To appraise the clinical and cost effectiveness of teprotumumab within its marketing authorisation for treating thyroid eye disease.
 
Status In progress
Technology type Medicine
Decision Selected
Reason for decision Anticipate the topic will be of importance to patients, carers, professionals, commissioners and the health of the public to ensure clinical benefit is realised, inequalities in use addressed, and help them make the best use of NHS resources
Process STA Standard
ID number 6432

Provisional Schedule

Committee meeting 11 June 2025
Expected publication 20 August 2025

Project Team

Project lead Louise Jafferally

Email enquiries

External Assessment Group Kleijnen Systematic Reviews Ltd

Stakeholders

Companies sponsors Amgen Limited (teprotumumab)
Others Department of Health and Social Care
  NHS England
Patient carer groups British Thyroid Foundation
  Changing Faces
  Eyecare Trust
  Fight for Sight
  Immunodeficiency UK
  Macular Society
  National Federation of the Blind of the UK
  OBAC (Organisation of Blind African Caribbeans)
  Royal National Institute of Blind People
  SeeAbility
  Sense
  South Asian Health Foundation
  Specialised Healthcare Alliance
  Thyroid Eye Disease Charitable Trust (TEDct)
  Thyroid Trust
  Thomas Pocklington Trust
Professional groups Association of Optometrists
  British and Irish Orthoptic Society
  British Geriatrics Society
  British Oculoplastic Surgical Society
  British Ophthalmic Anaesthesia Society (BOAS)
  British Society for Immunology
  British Thyroid Association
  College of Optometrists
  Optical Confederation
  Royal College of General Practitioners
  Royal College of Nursing
  Royal College of Ophthalmologists
  Royal College of Pathologists
  Royal College of Physicians
  Royal Pharmaceutical Society
  Royal Society of Medicine
  Society for Endocrinology
  UK Clinical Pharmacy Association
Associated public health groups Public Health Wales
  UK Health Security Agency
Comparator companies None
General commentators All Wales Therapeutics and Toxicology Centre
  Allied Health Professionals Federation
  Board of Community Health Councils in Wales
  British National Formulary
  Care Quality Commission
  Department of Health, Social Services and Public Safety for Northern Ireland
  Healthcare Improvement Scotland
  Medicines and Healthcare products Regulatory Agency
  National Association of Primary Care
  National Pharmacy Association
  NHS Confederation
  Scottish Medicines Consortium
  Wales Council for the Blind
  Welsh Endocrine and Diabetes Society
  Welsh Government
  Welsh Health Specialised Services Committee
Relevant research groups Cochrane Eyes and Vision Group
  Cochrane UK
  Eye Hope
  Genomics England
  Institute of Ophthalmology, University College London
  MRC Clinical Trials Unit
  National Eye Research Centre
  National Institute for Health Research

Timeline

Key events during the development of the guidance:

Date Update
29 October 2024 Invitation to participate
18 July 2024 - 15 August 2024 Consultation on suggested remit, draft scope and provisional stakeholder list of consultees and commentators: 6432
18 July 2024 In progress. Scoping commenced.
10 April 2024 Awaiting development. Status change linked to Topic Selection Decision being set to Selected

For further information on our processes and methods, please see our CHTE processes and methods manual